Teclistamab in Relapsed or Refractory Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Teclistamab in Relapsed or Refractory Multiple Myeloma
N. Engl. J. Med 2022 Jun 05;[EPub Ahead of Print], P Moreau, AL Garfall, NWCJ van de Donk, H Nahi, JF San-Miguel, A Oriol, AK Nooka, T Martin, L Rosinol, A Chari, L Karlin, L Benboubker, MV Mateos, N Bahlis, R Popat, B Besemer, J Martínez-López, S Sidana, M Delforge, L Pei, D Trancucci, R Verona, S Girgis, SXW Lin, Y Olyslager, M Jaffe, C Uhlar, T Stephenson, R Van Rampelbergh, A Banerjee, JD Goldberg, R Kobos, A Krishnan, SZ UsmaniFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.